RIETE Score for Risk of Hemorrhage in Pulmonary Embolism Treatment

• Use as an adjunct to clinical judgment rather than a standalone decision-making tool. 
• Regularly reassess bleeding risk during therapy, as the model captures only baseline risk and does not account for interval clinical changes.
• Predictive performance declines when applied beyond the initial 3 months of anticoagulation.
• Regardless of the management strategy chosen, informed consent remains essential.

• Low risk: Initiation of anticoagulation with standard monitoring is generally reasonable.
• Intermediate risk: Carefully weigh the risks and benefits of anticoagulation before initiating therapy.
• High risk: Consider alternative management strategies and closer monitoring in patients at high bleeding risk.

Risks and benefits of anticoagulation should be carefully considered in ALL patients prior to initiating therapy.